Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MAP2K2 Gene Mutation”

3 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 3 of 3 results

Testing effectiveness (Phase 2)Study completedNCT05054374
What this trial is testing

Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Who this might be right for
Breast CancerBreast Cancer Stage IVHER2-negative Breast Cancer+4 more
Memorial Sloan Kettering Cancer Center 6
Testing effectiveness (Phase 2)Ended earlyNCT04488003
What this trial is testing

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Who this might be right for
Advanced Solid TumorBRAF Gene MutationBRAF Gene Alteration+6 more
BioMed Valley Discoveries, Inc 104
Testing effectiveness (Phase 2)Ended earlyNCT04534283
What this trial is testing

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

Who this might be right for
CancerCancer MetastaticBRAF V600E+4 more
Anita Turk 16